rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AXSM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch
      Nov 16Yahoo FinanceAXSM
      Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge
      Nov 10Yahoo FinanceAXSM
      Is Axsome Therapeutics (AXSM) Fully Priced Given Its Sales Growth?

      Axsome Therapeutics has delivered a very large 5 year share price gain, yet the stock has pulled back sharply in recent months. That mix of long term gains and recent weakness puts a simple question in front of you as an investor: is today's valuation justified by the sales the business is generating? Over the past 5 years, Axsome Therapeutics shares have returned about 237.2%, so a lot of optimism is already baked into the price that now needs to be weighed against the company's sales...

      Nov 7Yahoo FinanceAXSM
      Axsome Therapeutics (AXSM) Stock Gets Fair Value Trim After Q3 Analyst Revisions
      Nov 6Yahoo FinanceAXSM
      Axsome: 3 Key Takeaways for Long-Term Investors | The Motley Fool

      A late-stage pipeline with 10 programs in development offers multiple growth catalysts beyond Auvelity's current commercial momentum.

      Nov 4The Motley FoolAXSM
      AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
      Nov 3Yahoo FinanceAXSM
      Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says
      Nov 3Yahoo FinanceAXSM
      Guggenheim lowers Axsome stock price target to $250 on valuation
      Nov 3Investing.comAXSM
      RBC Lowers Price Target on Axsome Therapeutics to $273 From $295, Keeps Outperform Rating
      Nov 3Yahoo FinanceAXSM
      Axsome Therapeutics to Participate in Upcoming Investor Conferences
      Nov 3Yahoo FinanceAXSM
      UBS cuts Axsome Therapeutics stock price target on sales trajectory
      Nov 3Investing.comAXSM
      B.Riley reiterates Buy on Axsome stock, keeps $300 target
      Nov 3Investing.comAXSMRILYRILYGRILYLRILYNRILYTRILYZ
      Axsome Therapeutics Inc (AXSM) (Q3 2026) Earnings Call Highlights: Revenue Tops $1 Billion Run ...
      Nov 3Yahoo FinanceAXSM
      Revenue Growth And Narrower Losses Could Change The Case For Axsome Therapeutics Stock
      Nov 3Yahoo FinanceAXSM
      AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat
      Nov 2Yahoo FinanceAXSM
      Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade) (NASDAQ:AXSM)
      Nov 2Seeking AlphaAXSM
      Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 2Yahoo FinanceAXSM
      Axsome (AXSM) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 2The Globe and MailAXSM
      What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
      Nov 2Yahoo FinanceAXSM
      Axsome Therapeutics stock hits 52-week low at 123.41 USD
      Nov 2Investing.comAXSM
      Axsome Q3 2026 slides: 52% revenue growth, stock falls on concerns
      Nov 2Investing.comAXSM
      Axsome Therapeutics Q3 2026 Earnings Call Transcript
      Nov 2BenzingaAXSM
      Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 2Yahoo FinanceAXSM
      Axsome Therapeutics Shares Rise 2.13% as Q3 Revenue Jumps 52% and Loss Narrows
      Nov 2Yahoo FinanceAXSM
      Axsome Therapeutics stock rises 2% on beat driven by strong product growth
      Nov 2Investing.comAXSM
      Axsome Therapeutics Inc earnings beat by $0.33, revenue topped estimates
      Nov 2Investing.comAXSM
      Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

      Axsome (AXSM) delivered earnings and revenue surprises of +63.77% and +5.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 2Yahoo FinanceAXSM
      Axsome: Q3 Earnings Snapshot
      Nov 2Yahoo FinanceAXSM
      Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

      Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth SYMBRAVO® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated Company to host conference call today at 8:00 AM Eastern Time NEW

      Nov 2Yahoo FinanceAXSM
      Axsome earnings ahead: Auvelity launch under microscope
      Nov 2Investing.comAXSM
      Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?
      Oct 29Yahoo FinanceAXSM
      Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility | The Motley Fool

      Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.

      Oct 28The Motley FoolAXSMMRNA
      Axsome Therapeutics stock may move 8.6% on earnings report
      Oct 26Investing.comAXSM
      Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

      Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 26Yahoo FinanceAXSM
      2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) | The Motley Fool

      These drugmakers are capitalizing on their pipeline successes.

      Oct 23The Motley FoolAXSMLLY
      Axsome Therapeutics Needs Auvelity Growth To Outrun Launch Costs (NASDAQ:AXSM)
      Oct 23Seeking AlphaAXSM
      Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

      AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

      Oct 21Yahoo FinanceAXSMJAZZ
      Mizuho reiterates Outperform on Axsome stock ahead of earnings
      Oct 21Investing.comAXSM
      Top 3 Health Care Stocks That Could Blast Off In October
      Oct 21BenzingaAXSMINSM
      UBS Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

      Detailed price information for Axsome Thera (AXSM-Q) from The Globe and Mail including charting and trades.

      Oct 16The Globe and MailAXSM
      Does Axsome Therapeutics (AXSM) Trade Above Fair Value On Sales?
      Oct 16Yahoo FinanceAXSM
      Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says
      Oct 14Yahoo FinanceAXSM
      RBC Capital reiterates Axsome Therapeutics stock rating at Outperform
      Oct 14Investing.comAXSM
      Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
      Oct 13Yahoo FinanceAXSMNBIX
      Axsome Therapeutics, Inc. (19X.F) Stock Price, News, Quote & History - Yahoo Finance

      Find the latest Axsome Therapeutics, Inc. (19X.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

      Oct 13Yahoo FinanceAXSM
      Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? | The Motley Fool

      Auvelity's Alzheimer's expansion could transform Axsome by 2030.

      Oct 12The Motley FoolAXSM
      Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities

      Detailed price information for Axsome Thera (AXSM-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailAXSM
      4 CNS Drug Stocks Worth Watching This World Mental Health Day
      Oct 9Yahoo FinanceAXSM
      RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating
      Oct 8Yahoo FinanceAXSM
      Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
      Oct 7Yahoo FinanceAXSM

      This is the newest page. Registered accounts read further back.